Evidence map›Paper›PMID 30707379›Full record

Observational studyEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2019

Amoxicillin/clavulanic acid+aminoglycoside as empirical antibiotic treatment in severe community-acquired infections with diagnostic uncertainty.

Johan Courjon, David Chirio, Elisa Demonchy, Céline Michelangeli, Nicolas Degand, Pierre-Marie Roger

Abstract readComparative StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Urinary tract infection and antibiotic use around ureteral stent insertion for urolithiasis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Johan CourjonInfectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France. courjon.j@chu-nice.fr.ORCID http://orcid.org/0000-0002-0445-5104
David ChirioInfectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France.
Elisa DemonchyInfectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France.
Céline MichelangeliInfectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France.
Nicolas DegandBactériologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France.
Pierre-Marie RogerInfectiologie, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice, France.
Centre Hospitalier Universitaire de Nice · FRInserm · FRUniversité Côte d'Azur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diagnostic uncertainty is common in the emergency room and multidrug-resistant bacteria emerge in the community setting, implying to establish the most efficient empirical antibiotic therapy (eEAT). Our aim was to identify such eEAT, considering that in case of DU with severe clinical presentation, most prescribers would propose an empiric combination (EC). The medical dashboard of our ward records prospectively 28 characteristics of each hospitalization including hospitalization motive, final diagnosis, and all antibiotics prescribed. All patients with community-acquired bacteremia (CAB) were included. DU was defined by a discrepancy between suspected diagnosis in the emergency room and final diagnosis. eEAT was defined by in vitro activity of at least one prescribed compound. Finally, independently from the dashboard, we retrospectively compared 2 CTs: amoxicillin/clavulanic acid (AMC)+gentamicin (G) and cefotaxime (3GC)+G. One thousand thirty-four patients with a final diagnosis of CAB were identified from July 2005 to June 2018, including 357 DU (35%) at baseline. eEAT (n = 553) was associated with a trend towards a lower death rate compared to inefficient therapies: 5.4 vs 10.0% (p = 0.053), and effective antibiotic reassessment was the most protective factor against an unfavorable outcome: 0.34 (0.16-0.71). Bacteria involved in case of UD were resistant to AMC+G and to 3GC+G in 8.1% and 12.8% of patients, respectively. Diagnostic uncertainty was a frequent event requiring antibiotic reassessment. As the latter was not systematically realized, the best eEAT is required and AMC+aminoglycoside should be considered.

Indexed as

AdultAgedAged, 80 and overAminoglycosidesAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsBacteremiaBacteriaCommunity-Acquired InfectionsDrug Resistance, Multiple, BacterialDrug Therapy, CombinationFemaleHumansMaleMiddle AgedRetrospective StudiesAminoglycosidesAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsBacteremiaCommunity-acquired infectionEmpirical antibiotic therapyESBL EnterobacteriaceaeOutcome

Identifiers

PMID30707379
OpenAlexW2912156141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.